GleamWall
中文EN

ARMP Armata Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 921114 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-135.9%
TTM EPS YoY-151.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-127.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets306.1%
Debt / equity—
Current ratio0.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-96.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$23.72M$34.43M
SG&A expense$12.41M$13.18M
Operating income-$36.63M-$42.44M
Pretax income-$173.80M-$18.92M
Net income-$173.80M-$18.92M
EBITDA-$35.10M-$41.11M
EPS (basic)-4.80-0.52
EPS (diluted)-4.80-0.89
Weighted avg. shares (diluted)36.24M59.06M
Balance sheet
Cash & equivalents$8.69M$14.77M
Current assets$10.67M$11.31M
PP&E, net$12.19M$13.24M
Goodwill$3.49M$3.49M
Intangibles$10.26M$10.26M
Total assets$76.88M$86.44M
Current liabilities$8.95M$48.25M
Total liabilities$295.48M$134.46M
Shareholders' equity-$218.60M-$48.02M
Shares outstanding36.43M36.18M
Cash flow statement
Operating cash flow-$25.76M-$37.55M
Capital expenditure$542,000$1.88M
Free cash flow-$26.30M-$39.43M
Investing cash flow-$542,000-$1.88M
Financing cash flow$25.61M$34.96M
Depreciation & amortization$1.53M$1.32M
Stock-based compensation$2.61M$2.89M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.